AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheim...

Full description

Saved in:
Bibliographic Details
Main Authors DAVID SATIJN, TOM VINK, FLORENCE SOTTY, KARINA FOG, LILIANA CHRISTINA PEREIRA MONTEZINHO, PAUL PARREN, EDWARD VAN DEN BRINK, IBRAHIM JOHN MALIK, LOUISE BUUR VESTERAGER, RIK RADEMAKER, PEKKA KALLUNKI, ANN-LOUISE BERGSTROM
Format Patent
LanguageEnglish
Published 27.12.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy. (fig. 7)
Bibliography:Application Number: MY2017PI01926